| Keywords: |
controlled study; treatment outcome; survival rate; clinical trial; doxorubicin; fluorouracil; placebo; advanced cancer; drug potentiation; united states; united states food and drug administration; methotrexate; colorectal cancer; controlled clinical trial; phase 2 clinical trial; antimetabolites, antineoplastic; randomized controlled trial; editorial; irinotecan; drug synergism; survival time; statistical analysis; randomized controlled trials; folinic acid; outcomes research; loperamide; phase 1 clinical trial; oxaliplatin; thymidylate synthase; leucovorin; hematologic disease; placebos; raltitrexed; trimetrexate; clinical trials, phase ii; dihydropyrimidine dehydrogenase; clinical trials, phase i; humans; human; priority journal
|
